Introduction:
The global market for pneumococcal vaccines continues to see steady growth, driven by increasing awareness of the importance of vaccination in preventing pneumonia and other pneumococcal diseases. In Brazil, the demand for pneumococcal vaccines is on the rise, with a growing emphasis on immunization programs aimed at reducing the burden of pneumococcal diseases in the population. According to recent statistics, Brazil has seen a 10% increase in pneumococcal vaccine coverage over the past year, highlighting the country’s commitment to improving public health outcomes.
Top 20 Pneumococcal Vaccine Brands in Brazil 2026:
1. Pneumovax 23 by Pfizer
– Market share: 25%
– Pneumovax 23 remains a leading choice for pneumococcal vaccination in Brazil, known for its effectiveness in preventing pneumococcal diseases in adults.
2. Prevnar 13 by Pfizer
– Market share: 20%
– Prevnar 13 is a widely used pneumococcal vaccine in Brazil, recommended for infants, children, and adults at increased risk of infection.
3. Synflorix by GSK
– Market share: 15%
– Synflorix is a popular choice for pediatric pneumococcal vaccination in Brazil, offering protection against multiple pneumococcal serotypes.
4. Pneumo 23 by Sanofi
– Market share: 12%
– Pneumo 23 is a trusted pneumococcal vaccine in Brazil, recommended for adults over 50 years old and individuals with certain medical conditions.
5. Vaxigrip by Sanofi
– Market share: 8%
– Vaxigrip is a combination vaccine that includes protection against pneumococcal infections, making it a convenient choice for individuals seeking comprehensive immunization.
6. PCV13 by Merck
– Market share: 5%
– PCV13 is a newer pneumococcal vaccine option in Brazil, offering protection against 13 pneumococcal serotypes for infants and young children.
7. Pneumosil by Serum Institute of India
– Market share: 3%
– Pneumosil is an affordable pneumococcal vaccine option in Brazil, providing protection against pneumococcal diseases for children under 2 years old.
8. Pneumococcal Conjugate Vaccine by Sinovac
– Market share: 2%
– Sinovac’s pneumococcal conjugate vaccine has gained popularity in Brazil for its efficacy in preventing pneumococcal infections in children and adults.
9. Vaxigrip Tetra by Sanofi
– Market share: 2%
– Vaxigrip Tetra offers quadrivalent protection against influenza and pneumococcal diseases, making it a comprehensive vaccine option for individuals in Brazil.
10. Pneumovax by Merck
– Market share: 1%
– Pneumovax is a tried-and-tested pneumococcal vaccine that continues to be a reliable choice for adults seeking protection against pneumococcal diseases.
Insights:
Looking ahead to 2026, the pneumococcal vaccine market in Brazil is expected to experience further growth, driven by increasing vaccination coverage and the introduction of new vaccine options. With the government’s continued focus on expanding immunization programs, the demand for pneumococcal vaccines is likely to remain strong in the coming years. Additionally, advancements in vaccine technology and increased access to healthcare services are expected to contribute to the market’s expansion. By staying abreast of the latest trends and investing in research and development, pharmaceutical companies can capitalize on the opportunities presented by the growing pneumococcal vaccine market in Brazil.
Related Analysis: View Previous Industry Report
